Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
▴ In ten large, well-controlled, randomised trials (n = 203 to 1089), valdecoxib, a selective inhibitor of cyclo-oxygenase-2, was significantly more effective than placebo in the treatment of osteoarthritis, rheumatoid arthritis and pain associated with primary dysmenorrhoea, and for postsurgical analgesia.
▴ Valdecoxib 1.25 to 10mg twice daily and valdecoxib 10mg once daily were more effective than placebo for the relief of pain in patients with osteoarthritis of the knee, and dosages above 5mg twice daily were similar in efficacy to naproxen 500mg twice daily. Similarly, valdecoxib 5 and 10 mg/day were as effective far osteoarthritis of the hip as naproxen 500mg twice daily.
▴ In patients with rheumatoid arthritis, valdecoxib 10, 20 or 40 mg/day was significantly more effective than placebo, and similar in efficacy to naproxen 500mg twice daily; there were no significant differences in efficacy between the three dosages of valdecoxib.
▴ Valdecoxib 20 or 40mg administered 1 to 3 hours before and 12, 24 and 36 hours after hip arthroplasty provided significantly better analgesia than placebo, and significantly reduced the amount of morphine taken by patients.
▴ Single doses of valdecoxib 10 to 80mg administered before foot or oral surgery provided significantly better analgesia than placebo; when administered after oral surgery, valdecoxib 20 or 40mg provided greater sustained analgesia than oxycodone 10mg/paracetamol 1000mg or rofecoxib 50mg.
▴ In contrast to three nonselective nonsteroidal anti-inflammatory drugs (NSAIDs), valdecoxib 40mg twice daily did not cause significant changes in platelet function and bleeding times.
▴ Chronic users of NSAIDs who were switched to valdecoxib 10 or 20 mg/day for 12 weeks experienced significantly fewer gastroduodenal erosions or ulcers than patients receiving ibuprofen 2400 mg/day or diclofenac 150 mg/day for 12 weeks.
▴ Valdecoxib was generally well tolerated in clinical trials, with a similar incidence of adverse events to placebo.
- Adams EH, Hunter TS, Williams T. New options in the treatment of arthritis. J Manage Care Pharm 1999 Sep 31; 5: 443–8
- Carr DB, Goudas LC. Acute Pain. Lancet 1999 Jun 12; 353: 2051–8 CrossRef
- Botting JH. Nonsteroidal antiinflammatory agents. Drugs Today 1999 Apr; 35: 225–35
- Cheer SM, Goa KL. Parecoxib (parecoxib sodium). Drugs 2001; 61(8): 1133–41; discussion 1142-3 CrossRef
- Fiechtner JJ, Sikes D, Recker D. A double-blind, placebo-controlled dose ranging study to evaluate the efficacy of valdecoxib, a novel COX-2 specific inhibitor, in treating the signs and symptoms of osteoarthritis of the knee [abstract no. OP0048]. European Congress of Rheumatology; 2001 June 13–16; Prague, Czech Republic
- Daniels SE, Talwalker S, Hubbard RC, et al. Pre-operative valdecoxib, a COX-2 specific inhibitor, provides effective and long lasting pain relief following oral surgery [abstract no. A-810]. American Society of Anesthesiologists; 2001 Oct 13–17; New Orleans, Louisiana.
- Dejardins PJ, Talwalker S, Hubbard RC, et al. Pre-operative administration of valdecoxib, a potent COX-2 specific inhibitor, provides effective post-operative analgesia [abstract no. A-811]. American Society of Anesthesiologists; 2001 Oct 13–17; New Orleans, Louisiana
- Camu F, Beecher T, Recker DP, et al. Valdecoxib, a COX-2-specific inhibitor, is an efficacious, opioid-sparing analgesic in patients undergoing hip arthroplasty. Am J Ther 2002 Jan 28; 9(1): 43–51 CrossRef
- Talley JJ, Brown DL, Carter JS, et al. 4-[5-Methyl-3-pheny-lisoxazol-4-yl]-benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX- 2. J Med Chem 2000 Mar 9; 43(5): 775–7 CrossRef
- Leese PT, Recker D, Kuss ME. The novel COX-2 specific inhibitor, valdecoxib, does not affect platelet function in healthy adults [abstract no. 043]. European Congress of Rheumatology; 2001 June 13–16; Prague, Czech Republic.
- Leese PT, Recker D, Kuss ME. A double-blind, placebo-controlled study to evaluate the effects of valdecoxib, a novel COX-2 specific inhibitor, on platelet function in the elderly [abstract no. 042]. European Congress of Rheumatology; 2001 June 13–16; Prague, Czech Republic.
- Pharmacia Corporation. Bextra, valdecoxib tablets. Product information [online]. Available from URL: http://www.pnu.com [Accessed 2002 Aug 12]
- Kharasch E, Ibrahim A, Karim A, et al. Effects of parecoxib, a parenteral COX-2 specific inhibitor, on the pharmacokinetics and clinical effects of fentanyl and alfentanil [abstract no. A-450]. American Society of Anesthesiologists; 2001 Oct 13–17; New Orleans, Louisiana.
- Noroian G, Clive D. Cyclo-oxygenase-2 inhibitors and the kidney: a case for caution. Drug Saf 2002; 25(3): 165–72 CrossRef
- Kivitz A, Eisen G, Zhao WW, et al. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. J Fam Pract 2002 Jun;51(6):530–7
- Makarowski W, Zhao WW, Bevirt T, et al. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cartilage 2002 Apr; 10(4): 290–6 CrossRef
- Bensen W, Weaver A, Espinoza L, et al. Valdecoxib, a new COX-2 specific inhibitor, is effective in treating the signs and symptoms of rheumatoid arthritis [abstractno. 1896]. Arthritis Rheum 2001; 44 (9 Suppl.): 369
- Daniels SE, Desjardins PJ, Talwalker S, et al. The analgesic efficacy of valdecoxib vs. oxycodone/ acetaminophen after oral surgery. J Am Dent Assoc 2002 May; 133(5): 611–21
- Fricke J, Varkalis J, Zwillich S, et al. Valdecoxib is more efficacious than rofecoxib in relieving pain associated with oral surgery. Am J Ther 2002 Mar; 9(2): 89–97 CrossRef
- Daniels DE, Torris S, Snabes MC. Efficacy of valdecoxib versus naproxen sodium in primary dysmenorrhea. Obstet Gynecol 2002; 99 Suppl.: 30S–1S
- Camu F, Beecher T, Talwalker S, et al. The COX-2 specific inhibitor valdecoxib is opioid-sparing and provides effective analgesia in primary hip arthroplasty patients [abstract no. A-809]. American Society of Anesthesiologists; 2001 Oct 13–17; New Orleans, Louisiana.
- Goldstein JL, Fakouhi KM, Zhao WW, et al. Reduced incidence of gastroduodenal ulcers with valdecoxib compared to ibuprofen and diclofenac in patients with osteoarthritis: a multicenter trial [abstract no. 3032]. Gastroenterology 2001 Apr; 120 Suppl. 1: 597
- Goldstein JL, Stenson W, Agrawal N, et al. Valdecoxib is associated with a significantly lower incidence of ulcer complications and symptomatic ulcers in arthritis patients as compared to NSAID. [abstract no. T1503] Gastroenterology2002 Apr; 122 Suppl. 1: A469
- Goldstein JL, Kent J, Shu V, et al. Valdecoxib is less ulcerogenic than conventional NSAIDs in osteoarthritis (OA) and rheumatoid arthritis (RA) patients with high risk of peptic ulcer disease [abstract no. M1731]. Gastroenterology 2002 Apr; 122 Suppl. 1: A344
Volume 62, Issue 14 , pp 2059-2071
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors